Biotech Values

[DewDiligence]

OCRX’s pro forma cash at 6/30/15 was $51.2M*:

http://www.sec.gov/Archives/edgar/data/1274644/000127464415000040/oceratherapeuticsreportsse.htm

The company expects to burn $11-15M during 2H15, leaving a year-end 2015 cash balance of $36.2 - $40.2M. From the above link:

Following receipt of the initial $10.0 million tranche from the recent debt facility, Ocera believes that it has sufficient cash to fund its operations to mid-2017 based on its current operating plan. If Ocera receives the second $10.0 million tranche of the debt facility, which is subject to the achievement of certain financial and clinical milestones, the company expects that it will have cash to fund its operations to the fourth quarter of 2017.

In either case, there’s now enough cash to get to the reporting of data from the STOP-HE study.

*The actual cash balance on 6/30/15 was $41.2M, and OCRX received a $10M loan on 7/30/15 (#msg-115827192).